Werewolf Therapeutics Analyst Ratings
Werewolf Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/31/2023 | 453.04% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 09/19/2023 | 453.04% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 09/15/2023 | 453.04% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 08/24/2023 | 231.82% | Wedbush | → $9 | Initiates Coverage On | → Outperform |
| 08/10/2023 | 453.04% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/25/2023 | 206.01% | EF Hutton | → $8.3 | Assumes | → Buy |
| 05/12/2023 | 268.69% | B of A Securities | $9 → $10 | Maintains | Buy |
| 05/11/2023 | 453.04% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 03/24/2023 | 206.01% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 03/23/2023 | 231.82% | B of A Securities | → $9 | Reiterates | Buy → Buy |
| 03/23/2023 | 453.04% | HC Wainwright & Co. | $20 → $15 | Reiterates | → Buy |
| 02/27/2023 | 206.01% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 02/17/2023 | 206.01% | EF Hutton | → $8.3 | Reiterates | → Buy |
| 01/30/2023 | 194.95% | B of A Securities | $9 → $8 | Maintains | Buy |
| 12/05/2022 | 206.01% | EF Hutton | → $8.3 | Initiates Coverage On | → Buy |
| 06/02/2022 | 637.38% | HC Wainwright & Co. | → $20 | Assumes | → Buy |
| 05/11/2022 | 526.77% | SVB Leerink | $18 → $17 | Maintains | Outperform |
| 11/19/2021 | 932.33% | SVB Leerink | $29 → $28 | Maintains | Outperform |
| 09/10/2021 | 858.6% | B of A Securities | → $26 | Initiates Coverage On | → Buy |
| 05/25/2021 | 747.99% | Evercore ISI Group | → $23 | Initiates Coverage On | → Outperform |
| 05/25/2021 | 969.2% | SVB Leerink | → $29 | Initiates Coverage On | → Outperform |
| 05/25/2021 | 711.12% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 05/25/2021 | 1079.81% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月31日 | 453.04% | HC Wainwright公司 | →$15 | 重申 | 购买→购买 |
| 2023/09/19 | 453.04% | HC Wainwright公司 | →$15 | 重申 | 购买→购买 |
| 2023/09/15 | 453.04% | HC Wainwright公司 | →$15 | 重申 | 购买→购买 |
| 2023年08月24日 | 231.82% | 韦德布什 | →$9 | 开始承保 | →跑赢大盘 |
| 2023年08月10日 | 453.04% | HC Wainwright公司 | →$15 | 重申 | 购买→购买 |
| 2023年05月25日 | 206.01% | EF Hutton | →$8.3 | 假设 | →购买 |
| 2023年05月12日 | 268.69% | B of A证券 | $9→$10 | 维护 | 买 |
| 2023年05月11日 | 453.04% | HC Wainwright公司 | →$15 | 重申 | 购买→购买 |
| 03/24/2023 | 206.01% | EF Hutton | →$8.3 | 重申 | →购买 |
| 03/23/2023 | 231.82% | B of A证券 | →$9 | 重申 | 购买→购买 |
| 03/23/2023 | 453.04% | HC Wainwright公司 | $20→$15 | 重申 | →购买 |
| 02/27/2023 | 206.01% | EF Hutton | →$8.3 | 重申 | →购买 |
| 02/17/2023 | 206.01% | EF Hutton | →$8.3 | 重申 | →购买 |
| 2023年1月30日 | 194.95% | B of A证券 | $9→$8 | 维护 | 买 |
| 12/05/2022 | 206.01% | EF Hutton | →$8.3 | 开始承保 | →购买 |
| 06/02/2022 | 637.38% | HC Wainwright公司 | →$20 | 假设 | →购买 |
| 2022年05月11日 | 526.77% | SVB Leerink | $18→$17 | 维护 | 跑赢大盘 |
| 2021年11月19日 | 932.33% | SVB Leerink | $29→$28 | 维护 | 跑赢大盘 |
| 09/10/2021 | 858.6% | B of A证券 | →$26 | 开始承保 | →购买 |
| 2021/05/25 | 747.99% | Evercore ISI集团 | →$23 | 开始承保 | →跑赢大盘 |
| 2021/05/25 | 969.2% | SVB Leerink | →$29 | 开始承保 | →跑赢大盘 |
| 2021/05/25 | 711.12% | 杰富瑞 | →$22 | 开始承保 | →购买 |
| 2021/05/25 | 1079.81% | HC Wainwright公司 | →$32 | 开始承保 | →购买 |
What is the target price for Werewolf Therapeutics (HOWL)?
狼人治疗公司(Howl)的目标价格是多少？
The latest price target for Werewolf Therapeutics (NASDAQ: HOWL) was reported by HC Wainwright & Co. on October 31, 2023. The analyst firm set a price target for $15.00 expecting HOWL to rise to within 12 months (a possible 453.04% upside). 15 analyst firms have reported ratings in the last year.
狼人治疗公司(纳斯达克：HOWL)的最新目标价是由HC Wainwright&Co.于2023年10月31日报道的。这家分析公司将目标价定为15美元，预计Howl将在12个月内上升(可能上涨453.04%)。过去一年，有15家分析公司公布了评级。
What is the most recent analyst rating for Werewolf Therapeutics (HOWL)?
狼人治疗公司(Howl)的最新分析师评级是多少？
The latest analyst rating for Werewolf Therapeutics (NASDAQ: HOWL) was provided by HC Wainwright & Co., and Werewolf Therapeutics reiterated their buy rating.
狼人治疗公司(纳斯达克代码：HOWL)的最新分析师评级是由HC Wainwright&Co.提供的，狼人治疗公司重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Werewolf Therapeutics (HOWL)?
狼人治疗公司(Howl)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Werewolf Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Werewolf Therapeutics was filed on October 31, 2023 so you should expect the next rating to be made available sometime around October 31, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与狼人治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。狼人治疗公司的上一次评级是在2023年10月31日提交的，所以你应该预计下一次评级将在2024年10月31日左右的某个时候提供。
Is the Analyst Rating Werewolf Therapeutics (HOWL) correct?
分析师对狼人治疗公司(Howl)的评级正确吗？
While ratings are subjective and will change, the latest Werewolf Therapeutics (HOWL) rating was a reiterated with a price target of $0.00 to $15.00. The current price Werewolf Therapeutics (HOWL) is trading at is $2.71, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的狼人治疗(HOWL)评级被重申，目标价在0.00美元到15.00美元之间。狼人治疗公司(Howl)目前的交易价格为2.71美元，在分析师的预测范围内。